Oncodesign Precision Medicine (OPM), a French biopharmaceutical company specializing in precision medicine for resistant and metastatic cancers, has secured a €250,000 investment grant from the Bourgogne Franche-Comté Region. The funding is part of a regional support program designed to boost competitiveness and growth among innovative small and medium enterprises developing strategic technological expertise.
Regional Investment in Innovation
The grant will enable OPM to strengthen its technological and scientific capabilities, particularly focusing on its portfolio of innovative drug candidates targeting indications with unmet medical needs in chronic inflammatory digestive diseases, immuno-oncology, and Parkinson's disease.
"This grant from the Bourgogne Franche-Comté Region is a strong recognition of our expertise in precision medicine," said Philippe Genne, Co-founder and CEO of Oncodesign Precision Medicine. "It will enable us to consolidate our position as an innovative player in oncology research. We are proud to be based in a region that invests in research and innovation."
Karine Lignel, Co-founder and Chief Operating Officer, added that the funding "strengthens our ability to develop our technologies" and "illustrates the confidence of public partners in OPM's potential and our capacity for innovation."
Clinical Pipeline Progress
OPM currently has two kinase inhibitors in clinical development. OPM-101, intended for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, has demonstrated a significant therapeutic margin and absence of toxicity in its phase I trial with healthy volunteers. The company has scheduled the start of phase 1b/2a trials in oncology for September 2025.
OPM-201, initially licensed to Servier for Parkinson's disease treatment, completed its phase I trial in healthy volunteers at the end of 2024 and has been reintegrated into OPM's portfolio.
Technology Platform Development
Both clinical candidates originate from OPM's Nanocyclix® technology platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. The company has built a library of 12,000 molecules and plans to integrate artificial intelligence to accelerate drug candidate discovery while reducing development costs.
OPM operates two additional technology platforms: OncoSNIPER for therapeutic target selection using artificial intelligence, which includes a partnership with Servier for pancreatic cancer target identification, and PROMETHE® for designing and selecting radiolabeled biological molecules for systemic radiotherapy, with ongoing partnership discussions with vectorization manufacturers.
Company Background
Founded in 2022 by Philippe Genne, Jan Hoflack, and Karine Lignel, OPM is based in Dijon at the heart of the university and hospital cluster and employs 14 people. The company focuses on discovering treatments for resistant and metastatic cancers through precision medicine approaches.
